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ABSTRACT
Background. Sodium thiosulphate (NaTS) is mostly used in
haemodialysis (HD) patients with calcific uraemic arteriolop-
athy. This double-blind, randomized, placebo-controlled study
assessed the effect of NaTS on progression of cardiovascular cal-
cifications in HD patients.
Methods. From 65 screened patients, we recruited 60 patients
with an abdominal aorta Agatston calcification score 100.
Thirty patients were randomized to receive NaTS 25 g/1.73m2
and 30 patients to receive 100mL of 0.9% sodium chloride in-
travenously during the last 15min of HD over a period of
6months. The primary endpoint was the absolute change of the
abdominal aortic calcification score.
Results. The abdominal aortic calcification score and calcifica-
tion volume of the abdominal aorta increased similarly in both
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treatment groups during the trial. As compared with the saline
group, patients receiving NaTS exhibited a reduction of their il-
iac artery calcification score (1376 641 versus 245 6 755;
P¼ 0.049), reduced pulse wave velocity (9.6 6 2.7 versus
11.46 3.6; P¼ 0.000) and a lower carotid intima-media thick-
ness (0.77 6 0.1 versus 0.83 6 00.17; P¼ 0.033) and had better
preservation of echocardiographic parameters of left ventricular
hypertrophy. No patient of the NaTS group developed new car-
diac valve calcifications during the trial as compared with 8 of
29 patients in the saline group. By univariate analysis, NaTS
therapy was the only predictor of not developing new valvular
calcifications. No adverse events possibly related to NaTS infu-
sion were noted.
Conclusions.While NaTS failed to retard abdominal aortic cal-
cification progress, it positively affected calcification progress in
iliac arteries and heart valves as well as several other cardiovas-
cular functional parameters.
Keywords: abdominal aorta, iliac arteries, sodium thiosulphate,
valvular calcification, vascular calcification
INTRODUCTION
Vascular calcification (VC) is a well-recognized risk factor for
cardiovascular events and mortality in the general population,
but particularly in patients with chronic kidney disease (CKD)
[1]. In patients with end-stage renal disease on chronic haemo-
dialysis (HD) or peritoneal dialysis, cardiovascular calcifications
are highly prevalent and, even in young patient’s, progress at a
rapid rate [2]. Clinical consequences may arise from impaired
blood flow through calcified arteries or cardiac valves, but par-
ticularly from the stiffer vasculature with increased cardiac
afterload [3], and this may explain the almost ubiquitous obser-
vation that cardiovascular calcifications in CKD potently pre-
dict mortality [3].
The pathogenesis of cardiovascular calcifications in CKD is
complex and involves accelerated ageing of the cardiovascular
system [4]; high calcification ‘pressure’, in particular due to al-
tered handling of serum phosphate and calcium in CKD; but
also reduced physiological defences against VC, in particular a
relative vitamin K deficiency, and consequently impaired action
of the main vascular wall calcification inhibitor matrix Gla pro-
tein [4].
So far, cardiovascular calcifications in CKD are mostly
considered as a one-way road with little evidence for sponta-
neous regression and even successful kidney transplantation
does not lead to resolution of calcification [5]. Therapeutic
approaches have focused on secondary prevention via lower-
ing of serum phosphate, reducing calcium loading and con-
trolling secondary hyperparathyroidism with calcimimetics
[6–9]. Trials focusing on correction of the vitamin K defi-
ciency in HD patients, such as our VitaVasK trial, are ongo-
ing [5, 10], and the first evidence suggests that direct
oral anticoagulant therapy may induce less calcification prog-
ress compared with vitamin K antagonist [11]. Increasing
serum magnesium (Mg) may also reduce the progression
of calcification via inhibiting calcium phosphate crystal
formation [12]. Other novel compounds to inhibit calcifica-
tion progress, such as SNF-472, are currently being evaluated
[13].
A conceptually different approach is the administration of
sodium thiosulphate [NaTS (Na2S2O3)], which can mobilize
calcium from deposits and forms highly soluble calcium thio-
sulphate complexes in addition to NaTS’s antioxidant and vaso-
dilatory activity [14, 15]. NaTS is a chelating agent used mainly
for cyanide poisoning [16], but it may also improve skin necro-
sis in uraemic arteriolopathy (calciphylaxis) and soft tissue cal-
cification of uraemic [17–19] and even non-uraemic origin [20,
21]. The first reports on the effects of NaTS on cardiovascular
calcifications in chronic HD patients are available as well [22,
23]. In these two non-randomized studies, progression of arte-
rial calcification in HD patients slowed or was arrested follow-
ing 4–5months of intravenous administration of NaTS at the
end of the HD session [22, 23]. Another pilot study adminis-
tered NaTS via the dialysate in six patients [24]. To our knowl-
edge, there is no published randomized, placebo-controlled
study on the treatment effect of NaTS on the progression of
cardiovascular calcifications in HD patients. We therefore
set up an interventional double-blind, randomized, placebo-
controlled study to determine the effect of NaTS given over
6months on the progression of cardiovascular calcification in
HD patients.
MATERIALS AND METHODS
Patients and trial protocol
The trial was double-blind, randomized, placebo-
controlled and conducted over 6months. Screening started in
March 2015 and therapy finished in December 2015. Of 230
patients in the Clinical Department of Renal Diseases,
Zvezdara University Medical Centre, we recruited 65 patients
who fulfilled the inclusion criteria and who were willing to
participate in the study. Given the exploratory nature of this
trial, no power calculations were possible (post hoc achieved
power was 90.6%). The study was approved by the Zvezdara
University Medical Center ethical board and all patients
signed informed consent after detailed information about the
study protocol.
Inclusion criteria were on chronic thrice-weekly HD for
>6months, age >18 years, abdominal aortic calcification
score (AACS) 100 determined using the Agatston method
[25, 26] and the ability to give informed consent. Exclusion
criteria were intolerance or allergy to NaTS, pregnancy, in-
volvement in another study, active/chronic inflammation, be-
ing on vitamin K antagonistic drugs, malignancy and life
expectancy<6months.
Patients received conventional bicarbonate HD three times
per week (4 h per session) using high-flux polysulfone mem-
branes. Dialysate calcium concentration ranged from 1.25 to
1.5mmol/L and dialysate magnesium was 1.0mmol/L.
Bicarbonate in the dialysis fluid was adjusted according to the
serum bicarbonate (S-HCO3
) level. Dialysis conditions and
medications were kept constant as far as possible throughout
the study.
Sodium thiosulphate and progression of vascular calcification 163
D
ow
nloaded from
 https://academ
ic.oup.com
/ndt/article-abstract/35/1/162/5640481 by Belgrade U
niversity user on 28 June 2020
Randomization was carried out by an unblinded member of
the team using an online programme (http:/www.graphpad.
com/quickcalcs/randomize1.cfm) to randomize patients into
two groups. NaTS and saline were filled into bottles of the same
appearance and they were prepared by the unblinded member
of the team in order to keep the participating clinicians blinded
to patient allocation. NaTS or saline delivered by the unblinded
member of the team was labelled with patient codes, depending
on their allocation. Patients of the NaTS group received NaTS
25 g/1.73m2 dissolved in 100mL saline intravenously during
the last 15min of every HD session, while patients of the saline
group received 100mL of 0.9% saline during the last 15min of
every HD session.
The primary endpoint of the trial was the absolute change in
the AACS determined using a 16-slice computed tomography
(CT) scanner and the Agatston method. Secondary endpoints
included changes in the abdominal aortic calcification volume
(AACV) score, iliac artery Agatston calcification score (IACS),
iliac artery calcification volume score (IACV), intima-media
thickness of the common carotid arteries (IMT CCAs), pulse
wave velocity (PWV), cardiac valve calcification and left ven-
tricular hypertrophy, all determined as described below. Finally,
adverse events were captured as reported by the patients and
treating physicians.
Demographic, biochemical and dialysis data
Patient characteristics were taken from the medical records
and included age, sex, dialysis vintage (months), presence of di-
abetes mellitus and hypertension and medication.
Routine laboratory data were captured as the average of
three measurements before the start and three at the end of the
trial. Samples for laboratory analyses were obtained at the start
of the HD procedure after a 3-day HD interval.
The adequacy of dialysis was assessed using Kt/V values cal-
culated using the Daugirdas formula [27]. Serum corrected cal-
cium was calculated using an online programme (https://www.
mdcalc.com/calcium-correction-hypoalbuminemia).
Diagnostic procedures
Non-contrast-enhanced CT scans of the abdomen were per-
formed using a GE Light Speed 16 multislice spiral CT scanner
(120 kVp, 75 mAs; GE Healthcare, Chicago, IL, USA).
Scanning was done in sequential 3.75mm thick layers. CT
images were transferred by a single observer who was blinded
to the treatment groups to a dedicated VITREA 2 workstation
(Vital Images, Minnetonka, MN, USA) equipped with a pro-
gramme to calculate the Agatston score and volume as de-
scribed previously [25, 26]. Intra-observer variability was 0.2%.
An aortic segment 5 cm proximal to the bifurcation of the ab-
dominal aorta was scored and analysed (AACS and AACV).
The common iliac artery was scored from the bifurcation of the
abdominal aorta to the bifurcation of the common iliac artery
and scores of the left and right iliac artery were combined to
yield the IACS and IACV. Progression of calcification was de-
fined as a difference between the follow-up and baseline square
root–transformed calcium volume scores 2.5mm/year
according to a previously described methodology [28].
Echocardiography was performed with a GE Vivid 7
machine using a 2.5-MHz probe allowingM-mode, two-dimen-
sional and pulsed Doppler measurements. Measurements were
made according to the recommendations of the American
Society of Echocardiography [29]. The following parameters
were determined: presence and localization of calcifications in
cardiac structures, left ventricular end-diastolic diameter
(LVEDD), left ventricular end-systolic diameter, ventricular
septum thickness in diastole (IVSD), left ventricular posterior
wall thickness in diastole (LPWD) and ejection fraction (EF).
Intra-observer variability was 4%.
Common carotid arteries were investigated by B-mode ul-
trasonography (using the SONOACE 7000 system with 7.5-
MHz linear transducers). IMT and carotid plaques were
assessed in both common carotid arteries 4 cm from the bulbs,
within carotid bulbs and within the first 2 cm of the internal
and external carotid arteries. IMT was calculated as the mean of
four measurements [30]. Plaques were defined as echogenic
structures showing protrusion into the lumen with focal widen-
ing that was 50% greater than the IMT of adjacent sites. Highly
echogenic plaques producing bright white echoes with ultra-
sound shadows were considered to be calcifications [29]. Intra-
observer variability was 7%.
PWV was determined using the Complior SP system
(Artech Medical, Pantin, France). PWV was measured utilizing
two sensors (one carotid and one femoral) simultaneously to
determine the velocity of the pulse in relation to the distance be-
tween the femoral artery and the suprasternal notch. Twomeas-
urements were performed by two observers and mean values
were calculated. Interobserver variability was 6%.
All diagnostic procedures were performed before and after
the study period of 6months and investigators for all tests were
blinded to the treatment arms.
Statistical analysis
Statistical calculations were performed using SPSS version
16.0 (SPSS, Chicago, IL, USA). Data were expressed as a per-
centage for discrete variables and as mean values for continuous
variables. Statistical analyses included exploratory descriptive
and analytic statistics. The independent sample t-test was used
to compare variables with normal distribution between differ-
ent groups. In cases where variables did not have a normal dis-
tribution, the Mann–Whitney U test was used. Paired tests for
differences between pre- and post-study values were calculated
using the paired samples t-test. Univariate and multivariate lo-
gistic regression analyses were used to assess factors associated
with calcification progression. All variables that were significant
in the univariate analysis were included in the multivariate
analysis. P-values <0.05 were considered to be statistically
significant.
RESULTS
Baseline characteristics
Of the 65 patients screened, 60 who had an AACS100 de-
termined using the Agatston method were considered eligible
for the study (Figure 1). Thirty patients were randomized to the
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NaTS group and 30 patients to the saline group. As shown in
Figure 1, four patients of the NaTS group dropped out of the
trial: one patient died after a stroke, one underwent surgery for
a splenic arterial aneurysm at another institution and was lost
to follow-up and two patients withdrew their consent for per-
sonal reasons. In the saline group, one patient withdrew in-
formed consent for personal reasons. Thus, at the end of the
trial, 55 patients were available for the final analysis using a per-
protocol approach.
Baseline demographic, dialysis and biochemical data of the
patients are shown in Tables 1 and 2. There were no significant
differences between the groups regarding any of the parameters
assessed. Therapeutic use of phosphate binders (only calcium
carbonate was used) and calcitriol was comparable in both
groups (Table 1). Other vitamin D analogues, native vitamin D
or calcimimetics were not used in any patient.
Primary endpoint
The AACS significantly increased after 6months of therapy
and there was no statistically significant difference in the abso-
lute change of the calcification score (DAACS) between the
NaTS and saline group (Table 3).
Secondary endpoints
Abdominal aortic calcification determined as a volume score
(AACV) instead of the Agatston score (AACS) progressed simi-
larly in both groups (Table 3).
As shown in Table 3, the mean Agatston score in the iliac ar-
teries decreased in the NaTS but not the saline group. The dif-
ference in absolute change of IACS (DIACS) between the two
groups was statistically significant (P¼ 0.049).
PWV and CCA IMT significantly decreased in the NaTS
group but not in the saline group (Table 3). In contrast,
neither the luminal diameter of the CCA nor the number of cal-
cified plaques changed significantly during the study in either
group.
Cardiac structure, function and valvular calcifications are
shown in Table 4. Cardiac parameters of left ventricular hyper-
trophy (LVEDD, IVSD and LPWD) significantly worsened in
the saline but not in the NaTS group. There were no patients
with newly calcified cardiac valves at the end of the trial in the
NaTS group, while eight patients in the saline group developed
de novo calcifications of the valves (Table 4).
Predictors of endpoints. Univariate logistic regression
analysis was used to assess the impact of several factors on the
probability of AACS progression in a model that contained 12
independent variables: gender, age, smoking, dialysis vintage,
Kt/V, diabetes, NaTS therapy, corrected calcium, serum phos-
phorus (S-PO4), phosphate binder, calcitriol and intact para-
thormone (iPTH). In this analysis, dialysis vintage {odds ratio
[OR] 0.99 [95% confidence interval (CI) 0.985–1.000], P ¼
0.044} and corrected serum calcium [S-Ca; OR 16.8 (95% CI
1.23–230.4), P¼ 0.034] were significant predictors of AACS
progression. However, by multivariate analysis, no factor signif-
icantly predicted AACS progression. By using the same predic-
tors in a univariate logistic regression model, we found that
none of the 12 parameters was a significant predictor of IACS
calcification progress or of CCA IMT reduction.
The analysis of risk factors for developing de novo valvular
calcifications showed that patients who received saline had an
OR of 9.5 to develop new valvular calcifications as compared
with those receiving NaTS [OR 9.5 (95% CI 1.10–82.4),
P¼ 0.041]. NaTS therapy was the only significant protective
factor in this univariate analysis.
Also, NaTS was the only significant predictor of reduction
of PWV. Patients who received NaTS had a 5.8-fold higher
chance to decrease their PWV [OR 5.89 (95% CI 1.62–21.4),
P¼ 0.007].
Safety data. Laboratory data before and after therapy are
shown in Table 2. Total albumin and corrected S-Ca decreased
significantly in both groups. Serum phosphate increased signifi-
cantly after 6months of therapy with NaTS but not with saline.
Uric acid fell significantly in the saline group only and iPTH
significantly increased in the NaTS group. All other parameters
did not change significantly over the course of the trial
(Table 4).
In terms of adverse events, one patient of the saline group
reported nausea. No other adverse events or intolerance possi-
bly related to NaTS were registered. In particular, patients in
the NaTS group failed to develop hypernatraemia, hyperten-
sion, anorexia, metabolic acidosis or changes in their anion gap.
Overall, there were 16 hospital admissions in the trial subjects
(10 in the NaTS group and 6 in the saline group): vascular ac-
cess complications (n¼ 10), gastrointestinal bleeding (n¼ 1),
peripheral vascular disease (n¼ 1), infection (n¼ 2), heart
FIGURE 1: Study flowchart.
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failure (n¼ 1) and hyperglycaemia (n¼ 1). None of the hospi-
talizations were considered to be related to NaTS treatment.
There was no fatal outcome in either group.
DISCUSSION
This randomized controlled clinical trial primarily aimed to an-
alyse the effect of NaTS on calcification of the abdominal aorta
in chronic HD patients with significant pre-existing calcifica-
tion. We selected abdominal aortic calcification as our primary
endpoint, given that it is a surrogate marker of asymptomatic
coronary artery disease and an independent predictor of cardio-
vascular events [31]. Also, abdominal aortic calcification pre-
cedes the occurrence of coronary artery calcification in HD
patients [32]. Our trial failed to observe significant effects of
NaTS on the primary study endpoint, namely the progression
of abdominal aortic calcification. In contrast, a number of sec-
ondary endpoints, including progression of iliac artery or cardiac
valve calcification, as well as several functional cardiovascular
parameters (PWV, CCA IMT, LVDD, IVSD and LPWD) were
Table 1. Baseline characteristics of the patients
Parameters NaTS group (n¼ 30) Saline group (n¼ 30) P-value
Males, % 56.7 70.0 0.211
Age (years), mean6 SD 63.86 13.2 64.16 9.7 0.938
Body weight (kg), mean6 SD 71.56 9.1 72.06 7.5 0.713
Active/previous smokers, n 7 9 0.230
Dialysis vintage (months), mean6 SD 104.46 80.5 103.76 75.1 0.972
Diabetes (main disease or comorbidity), % 23.3 20.0 0.500
ESRD assumed due to, % – – 0.210
Diabetes mellitus 10.0 10.0 –
Hypertension 50.0 56.7
Glomerulonephritis 20.0 3.3
Tubulointerstitial renal disease 13.3 16.7
ADPKD 0 5.0
Other 6.7 3.3
Dialysate calcium (mEq/L), mean6 SD 1.356 0.3 1.366 0.4 0.845
Patients receiving PO4 binders, % 20 23 0.932
Intake of elemental calcium from PO4
 binders (g/day), mean6 SD 1.366 0.61 1.386 0.54 0.541
Patients receiving calcitriol, % 14 13 0.593
Calcitriol (mg/week), mean6 SD 1.756 1.33 1.776 1.36 0.491
ADPKD, autosomal dominant polycystic kidney disease; SD, standard deviation.
Table 2. Laboratory data before and at the end of therapy with NaTS (pre-dialysis values obtained after a 3-day HD interval)
Laboratory parameters NaTS group (n¼ 26) Saline group (n¼ 29) P-value** (NaTS
versus saline group)
Before After P-value* Before After P-value* Before After
Total protein (g/L) 70.36 5.5 69.76 4.7 0.503 70.86 5.7 70.26 5.5 0.477 0.731 0.710
Serum albumin (g/L) 38.66 3.0 38.46 2.5 0.700 38.86 1.8 38.16 3.1 0.146 0.858 0.716
Uric acid (mg/L) 380.96 58.1 370.86 69.4 0.431 390.46 90.6 361.06 83.1 0.016 0.647 0.578
Cholesterol (mmol/L) 4.66 1.2 4.66 0.9 0.927 4.56 0.9 4.56 1.0 0.711 0.789 0.654
HDL (mmol/L) 1.16 0.4 1.26 0.4 0.593 1.26 0.4 1.16 0.4 0.539 0.589 0.433
LDL (mmol/L) 2.66 0.8 2.66 0.7 0.953 2.66 0.8 2.66 0.9 0.993 0.865 0.970
Triglycerides (mmol/L) 2.06 1.0 2.16 1.6 0.607 1.76 0.8 1.76 0.8 0.847 0.704 0.946
S-Na (mmol/L) 136.56 3.4 137.06 2.9 0.743 135.66 2.8 136.56 2.0 0.078 0.358 0.550
S-Cl (mmol/L) 102.76 2.9 102.16 3.5 0.424 102.36 .1 102.86 3.3 0.817 0.927 0.441
S-Mg (mmol/L) 1.436 0.2 1.416 0.1 0.599 1.316 0.1 1.326 0.1 0.243 0.007 0.050
S-Ca (mmol/L) 2.376 0.2 2.256 0.2 0.004 2.386 0.2 2.286 0.2 0.001 0.768 0.621
Corrected Ca (mmol/L) 2.636 0.3 2.396 0.2 0.002 2.626 0.3 2.436 0.3 0.000 0.926 0.539
S-PO4 (mmol/L) 1.416 0.4 1.686 0.5 0.002 1.446 0.4 1.456 0.3 0.809 0.838 0.051
S-HCO3 (mmol/L) 22.46 4 226 2.5 0.651 226 3 226 4 0.357 0.690 0.986
iPTH (pg/mL), median (IQR) 129.7 (59.8–256.1) 189 (69.1–403.8) 0.018a 110.1 (60.5–172.2) 79.9 (55.5–264.3) 0.068 0.443 0.225
Anion gap (mEq/L) 12.16 2.8 12.66 2.8 0.449 11.46 2.3 11.86 3.1 0.580 0.399 0.209
Hb (g/L) 1056 15 1036 16 0.537 1066 11 1066 16 0.984 0.906 0.161
Kt/V 1.546 0.35 1.486 0.41 0.276 1.496 0.32 1.426 0.30 0.056 0.807 0.463
Bold indicates statistical significance and correspond to head P-value (P-value*). Values presented as mean6 SD unless stated otherwise.
aBaseline (before) samples of only those patients finishing the trial entered the analyses.
*P-values refer to comparisons before and at the end of the study.
**P-values refer to comparisons before (NaTS versus saline) and after the study (NaTS versus saline).
HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; Hb, haemoglobin.
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positively and significantly affected by NaTS therapy. In the uni-
variate regression model, NaTS therapy was the only significant
protective factor against valvular calcification.
So far, two clinical studies have specifically addressed the
effect of intravenous NaTS on the progression of cardiovascular
calcification in HD patients. In the first one, 16 Thai patients
with significant coronary artery calcification received 12.5 g
NaTS twice weekly after HD for 4months and were matched to
16 patients with no specific intervention but similar baseline
calcification [22]. Progression of coronary artery calcification
occurred in 25% of the NaTS patients as compared with 63% of
the control patients [19]. In the second non-controlled study,
22 mostly African American patients with significant baseline
coronary artery calcification received 12.5–25 g of NaTS three
times per week over a 5-month period after each HD treatment
[23]. Despite NaTS therapy, coronary artery calcification scores
progressed in 14/22 subjects, but the absence of a control group
precludes firm conclusions [23]. Comparison of these two
studies with our present one is difficult given that the previous
studies focused on coronary arteries and the thoracic aorta and
enrolled patients with mostly different ethnicity, but more im-
portantly, they were not randomized, lacked controls in one
case [23] and used shorter treatment durations and/or possibly
different dosages of NaTS (see below). In addition, none of the
previous studies assessed the effects of NaTS on cardiac valves.
Another small pilot study analysed the effects of NaTS ad-
ministered via dialysis fluid at a concentration of 10 g/L to six
HD patients [24]. As compared with controls, this regimen
Table 4. Cardiac structure/function and calcification of cardiac valves before and at the end of therapy with NaTS
Echosonographic parameters NaTS group (n¼ 26) Saline group (n¼ 29) P-value** (NaTS
versus saline group)
Before After P-value* Before After P-value* Before After
LVEDD (mm), mean6 SD 47.16 8.5 47.76 7.7 0.512 47.36 6.4 50.06 7.0 0.013 0.583 0.241
LVDES (mm), mean6 SD 32.96 6.9 33.56 6.0 0.476 34.26 6.1 35.66 6.2 0.195 0.466 0.213
IVSD (mm), mean6SD 11.66 2.2 12.0 1.8 0.063 11.46 2.0 11.96 1.6 0.041 0.619 0.662
LPWD (mm), mean6 SD 11.36 2.2 11.66 1.5 0.242 10.86 1.6 11.76 1.4 0.000 0.426 0.973
EF (%), mean6 SD 54.26 7.2 53.16 6.9 0.282 54.86 7.0 53.86 7.8 0.227 0.717 0.571
Overall patients with calcified valves, n 20 20 1.000 20 28 0.008 –
Patients with calcified aortic valves, n 6 4 11 10
Patients with calcified mitral valves, n 5 3 1 3
Patients with calcified aortic plus
mitral valves, n
9 13 8 15
Bold indicates statistical significance and correspond to head P-value (P-value*).
*P-values refer to comparisons before and at the end of the study.
**P-values refer to comparisons before (NaTS versus saline) and after the study (NaTS versus saline).
Table 3. Parameters of vascular calcifications before and after therapy with NaTS
Parameters NaTS group (n¼ 26) Saline group (n¼ 29) P-value** (NaTS
versus saline group)
Before After P-value* Before After P-value* Before After
AACS, median (IQR) 3879 4823 0.003 4054 4478 0.002 0.993 0.879
(2036.8–5724.0) (2090.8–5889.3) (1175.5–7123) (1169.5–7564.5)
DAACS, mean6 SD 2646 487 3726 919 0.592
AACV, median (IQR) 3221.5 3710.5 0.006 3319 3406 0.001 1.000 0.866
(1566.3–4325.0) (1607.3–4487.0) (1001.5–5407) (992.5–5705)
DAACV, mean6 SD 1976 357 2826 703 0.543
IACS, median (IQR) 3903.5 3844.5 0.485 3394.5 3865 0.295 0.835 0.736
(808.5–7900.0) (954.5–7453.0) (831.5–8673.5) (774–9995.75)
DIACS, mean6 SD 1376 641 2456 755 0.049
IACV, median (IQR) 3129.5 2984.5 0.809 2723 3054 0.449 0.787 0.723
(663.8–5978.0) (784.3–5613.5) (692.5–6524.0) (674.5–7533.5)
DIACV, mean6 SD 886 495 1776 581 0.074
PWV (m/s), mean6 SD 11.46 3.6 9.66 2.7 0.000 10.46 2.8 10.46 2.7 0.574 0.363 0.332
CCA IMT (mm), mean6 SD 0.836 0.17 0.776 0.13 0.033 0.826 0.14 0.836 0.14 0.682 0.953 0.133
CCA LD (mm), mean6 SD 7.226 1.00 7.166 0.90 0.568 7.316 0.74 7.436 0.80 0.371 0.238 0.218
Patients with calcified
CCA plaques, n
17 17 1.000 21 23 0.500 –
Bold indicates statistical significance and correspond to head P-value (P-value*).
*P-values refer to comparisons within groups before and at the end of the study.
**P-values refer to comparisons before (NaTS versus saline) and after the study (NaTS versus saline) except for values DAACS, DAACV, DIACS and DIACV, where P-values refer to
the comparison between NaTS and saline groups.
IQR, interquartile range; LD, lumen diameter; SD, standard deviation.
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significantly reduced coronary artery calcification in four and
retarded progress in two patients. No side effects were regis-
tered during the study period of 6months.
Our study is notable for the lack of an NaTS-related benefit to
abdominal aortic calcification as opposed to retardation of iliac ar-
tery and cardiac valve calcification. One potential explanation for
these divergent effects might include the high statistical scatter of
AACSs, which, combined with only 6months of treatment, might
have prevented the detection of significant treatment effects.
However, statistical noise was similar in the assessment of iliac ar-
tery calcification, suggesting an alternative explanation, namely
different susceptibility of different cardiovascular regions to
NaTS. In this context, it is important to note that particular arte-
rial regions exhibit a different prevalence of calcification ranging
from 20% to 70% [33]. Variability of calcification processes in dif-
ferent blood vessels may be a consequence of blood vessel type
and size, blood flow characteristics, shear stress or even different
ontogenetic origin [34]. Our findings underline the complex path-
ophysiology of cardiovascular calcification and stress that diverse
factors may determine the susceptibility of various segments of
the vascular tree to VC and its progression. In addition, it is not
well established whether the composition of cardiovascular calcifi-
cation differs at a chemical level in different regions and whether
this toomight affect its responses to NaTS therapy.
Another important finding of our study is the effect of NaTS
therapy on arterial stiffness as assessed by PWV, that is, the
gold standard method [35]. By using different diagnostic tech-
niques, we and others have noted a relationship between PWV
and the degree of VC [36–38]. It is therefore of particular inter-
est that our treatment with NaTS led to a decrease in PWV, an
indirect sign of reduced calcification of the arterial bed, al-
though this relationship is still a matter of debate [39–41].
Another important parameter of vascular structure is CCA
IMT. As for PWV, NaTS decreased CCA IMT in our patients,
which is in contrast to previous North American observations
[23]. A very recent Taiwanese study [42] analysed arterial stiff-
ness by using a novel marker, the cardio-ankle vascular index
(CAVI). In agreement with our data, 12.5 g of NaTS given twice
weekly during the last hour of dialysis for 6months significantly
improved the CAVI and carotid–femoral PWV in the NaTS
group, in addition to decreased coronary artery calcification
scores [42]. In a subanalysis, NaTS benefits to arterial stiffness
were observed only in non-diabetic patients [42].
Our data are remarkably similar to a small, short-term
Polish intervention study with vitamin K supplements in non-
dialysed patients with CKD Stages 3–5 [43]. In that study,
9months of vitamin K failed to significantly affect VC progress
and the only highly significant benefit was observed for progres-
sion of carotid IMT [43].We speculate that significant retardation
or even resolution of VC may need more prolonged observation
periods, whereas IMT might be a more sensitive short-term
marker for vascular benefits of a particular intervention.
Stiffened arteries may have a significant impact on cardio-
vascular remodelling. Enhanced cardiac work in response to
stiffer arteries leads to left ventricular hypertrophy, thus poten-
tially contributing to heart failure and/or sudden cardiac death
[44]. While parameters of left ventricular hypertrophy (i.e.
LVDD, IVSD and LPWD) significantly deteriorated in our
saline group, they remained stable in the NaTS group. Again,
these data differ from those of Mathews et al. [23], who noted
no significant changes pre- versus post-NaTS in cardiac struc-
ture and systolic or diastolic cardiac function.
A possible adverse effect of NaTS therapy is anion gap acido-
sis [14]. In our group of patients, this was avoided by regular
controls of S-HCO3
, by the administration of NaTS during
HD and by adjusting the dialysate bicarbonate concentration in
patients with worsening metabolic acidosis. In another study,
NaTS therapy did not have a significant impact on inflamma-
tory, haemodynamic and bone mineral density parameters
[42]. Similarly, vertebral mineral density was stable in the Thai
NaTS and North American trials [22, 23], whereas bone min-
eral density of the total hip decreased in the Thai patients [22].
In addition to the lack of bone mineral data, our study has
further limitations. The relatively small number of patients and
short observation or therapy period may have masked potential
NaTS benefits. However, our trial is the largest that has been
performed so far. The question of the time of drug application
also deserves a comment since NaTS was administered during
the last 15min of HD rather than after HD as in previous trials
[22, 23]. The HD clearance of NaTS is high and most authors
recommended drug infusion either after the HD session or dur-
ing the last half hour of dialysis. In our patients, NaTS was well
tolerated and there were no study withdrawals or dose reduc-
tions due to adverse events. This difference could possibly ex-
plain why the NaTS tolerance in previous trials was much
worse, with nausea in all North American patients despite anti-
emetic therapy [23] and anorexia in 75% of the Thai patients
[22]. Finally, values of S-Ca immediately after administration
of NaTS were not available in our trial, so we have no insight
into possible transient hypocalcaemia in response to NaTS.
However, clinical signs of hypocalcaemia did not develop in any
patient and stable levels of iPTH in our NaTS-treated patients
argue against significant and prolonged NaTS effects on S-Ca.
In conclusion, NaTS proved to be a safe and effective thera-
peutic measure to reduce calcification at least in iliac arteries
and heart valves and to improve carotid IMT and PWV in addi-
tion to decreasing evidence of left ventricular hypertrophy. Our
study lends further support to initiating larger and more defini-
tive clinical trials of NaTS in dialysis patients.
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